DK442287A - Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat - Google Patents

Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat

Info

Publication number
DK442287A
DK442287A DK442287A DK442287A DK442287A DK 442287 A DK442287 A DK 442287A DK 442287 A DK442287 A DK 442287A DK 442287 A DK442287 A DK 442287A DK 442287 A DK442287 A DK 442287A
Authority
DK
Denmark
Prior art keywords
preparation
dopa
dihydroxyphenylalanine
procedure
active ingredient
Prior art date
Application number
DK442287A
Other languages
English (en)
Other versions
DK442287D0 (da
Inventor
Curt Henry Appelgren
Eva Christina Eskilsson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Publication of DK442287D0 publication Critical patent/DK442287D0/da
Publication of DK442287A publication Critical patent/DK442287A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Detergent Compositions (AREA)
DK442287A 1986-08-26 1987-08-25 Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat DK442287A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (2)

Publication Number Publication Date
DK442287D0 DK442287D0 (da) 1987-08-25
DK442287A true DK442287A (da) 1988-02-27

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK442287A DK442287A (da) 1986-08-26 1987-08-25 Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat

Country Status (15)

Country Link
US (1) US4981695A (da)
EP (1) EP0260236B1 (da)
JP (1) JPH0662405B2 (da)
AT (1) ATE58292T1 (da)
CA (1) CA1298198C (da)
DD (1) DD286107A5 (da)
DE (1) DE3766200D1 (da)
DK (1) DK442287A (da)
ES (1) ES2036221T3 (da)
FI (1) FI86689C (da)
HU (1) HU197211B (da)
MX (1) MX172918B (da)
NO (1) NO176549C (da)
PT (1) PT85591B (da)
SE (1) SE460947B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
CA2455621C (en) * 2001-07-26 2010-11-16 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
MXPA04009123A (es) * 2002-03-21 2005-09-08 C Hinz Martin Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina.
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US20050163850A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa
CA2549195A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1988887A2 (en) * 2006-01-13 2008-11-12 University of South Carolina Method and composition for the treatment of parkinson's disease
EP2086515A2 (en) * 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (da) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
EP0260236B1 (en) 1990-11-14
NO176549C (no) 1995-04-26
JPS63139128A (ja) 1988-06-10
EP0260236A1 (en) 1988-03-16
FI86689C (fi) 1992-10-12
NO176549B (no) 1995-01-16
CA1298198C (en) 1992-03-31
JPH0662405B2 (ja) 1994-08-17
HUT44438A (en) 1988-03-28
FI873672A0 (fi) 1987-08-25
ATE58292T1 (de) 1990-11-15
NO873589D0 (no) 1987-08-25
FI873672A (fi) 1988-02-27
NO873589L (no) 1988-02-29
SE460947B (sv) 1989-12-11
DE3766200D1 (de) 1990-12-20
SE8603582D0 (sv) 1986-08-26
PT85591B (pt) 1990-05-31
HU197211B (en) 1989-03-28
PT85591A (en) 1987-09-01
DD286107A5 (de) 1991-01-17
FI86689B (fi) 1992-06-30
US4981695A (en) 1991-01-01
DK442287D0 (da) 1987-08-25
ES2036221T3 (es) 1993-05-16
MX172918B (es) 1994-01-21
SE8603582L (sv) 1988-02-27

Similar Documents

Publication Publication Date Title
DK442287A (da) Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
DE3750145T2 (de) Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
MX9206305A (es) Bifenilpiridonas substitutas, procedimiento para su obtencion y medicamento que los contiene.
GR900300016T1 (en) A composition of matter for increasing intracellular atp levels and physical performance levels and for increasing the rate of wound repair
DK0615754T3 (da) Faste flupertinholdige orale administrationsformer med kontrolleret frigivelse af den aktive forbindelse
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
SE8803583L (sv) Farmaceutisk komposition
MX8958A (es) Procedimiento para obtener un preparado liofilizado que contiene ifosfamida.
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
SE8701077L (sv) Farmaceutisk beredning
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
ES2001104A6 (es) Un procedimiento para la preparacion de nuevos derivados sustituidos del acido 1,4-dihidro-3,5-piridindicarboxilico.
DK69287A (da) Temazepamkomposition og fremgangsmaade til fremstilling af samme
DK361083D0 (da) Fremgangsmade til fremstilling af 3-deazaguaninsulfonsyresalte samt farmaceutiske kompositioner indeholdende disse
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
ATS Application withdrawn